Advances in neoadjuvant immunotherapy for non-small cell lung cancer - Takeaways - MDSpire

Advances in neoadjuvant immunotherapy for non-small cell lung cancer

  • By

  • Xuehui Liu

  • Huasheng Li

  • Guangqi Dong

  • Yuyan Liu

  • Maobiao Ran

  • Dongbin Wang

  • June 12, 2026

  • 0 min

Share

  • 1

    Neoadjuvant immunotherapy, particularly immune checkpoint inhibitors, enhances anti-tumor immune responses in non-small cell lung cancer (NSCLC).

  • 2

    Combination strategies like dual PD-1/CTLA-4 blockade and chemoimmunotherapy improve survival and pathological response in operable NSCLC patients.

  • 3

    Neoadjuvant immune checkpoint inhibitors have shown safety and feasibility, achieving major pathological response in a significant number of patients.

  • 4

    Predictive biomarkers such as PD-L1 and tumor mutational burden can guide patient selection for neoadjuvant immunotherapy in NSCLC.

  • 5

    Neoadjuvant immunotherapy may improve long-term survival outcomes by promoting systemic immune responses and eradicating micrometastases before surgery.

Original Source(s)

Advances in neoadjuvant immunotherapy for non-small cell lung cancer

  • by Xuehui Liu, Huasheng Li, Guangqi Dong, Yuyan Liu, Maobiao Ran, Dongbin Wang

  • June 12, 2026

Related Content

Current status and trends of immune-related adverse events in lung cancer treated with immune checkpoint inhibitors: a bibliometric analysis of the past decade (2016–2025)

Exercise interventions for depressive symptoms in adults with lung and digestive cancer: a meta-analysis of randomized controlled trials

Use of PCSK9 Inhibitors Among Patients Receiving Immune Checkpoint Inhibitors for Cancer